Аннотация

Резюме

To evaluate the effectiveness of a fractionated levodopa dosing regimen in patients with Parkinson’s disease by assessing its impact on motor fluctuations, OFF periods, severity of motor impairment, and quality of life.

Материал и методы

The study was conducted at the Neurology Department of the National Medical Center of the Republic of Tajikistan “Shifobakhsh.” Seven patients with Parkinson’s disease (Hoehn–Yahr stages II–IV) were enrolled. 
The diagnosis was established according to the Movement Disorder Society (MDS) clinical diagnostic criteria, and all patients additionally underwent brain MRI. All participants had been receiving levodopa in a standard regimen (one tablet twice daily); subsequently, they were switched to a fractionated dosing schedule (½ tablet every 4 hours). 
Treatment efficacy was assessed at baseline and after 2 months using the Webster Rating Scale and the PDQ-25 questionnaire.

Результаты

 After 2 months of fractionated levodopa therapy, a significant reduction in motor impairment was observed (Webster score: 14,2 ± 3,1 to 10,1 ± 2,7; p < 0,01), along with a reduction of OFF periods to 1–2 hours per day. Daily activity scores improved by 21,7% (PD Self-Assessment: 92 to 72 points), mainly due to a decrease in morning akinesia and improved household activity.

Заключение

A fractionated levodopa dosing regimen is an effective and well-tolerated therapeutic strategy for patients with Parkinson’s disease, leading to a reduction in motor fluctuations, shorter OFF periods, and improved quality of life. These findings support the clinical feasibility of fractionated levodopa dosing as an accessible approach to therapy optimization at different stages of the disease.

Ключевые слова

Parkinson’s disease neurodegenerative diseases levodopa fractionated dosing motor fluctuations OFF periods.

Полный текст

Скачать статью в PDF

Полная версия статьи в формате PDF

Список литературы

  1. Alvarez MM, Cano-Herrera G, Osorio Martinez MF, et al. A comprehensive approach to Parkinson’s disease: addressing its molecular, clinical, and therapeutic aspects. Int J Mol Sci. 2024; 25(13): 7183. DOI: 10.3390/ijms25137183
  2. Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol. 2024; 20: 695–707. DOI: 10.1038/s41582-024-00945-0
  3. Gouda NA, Elkamhawy A, Cho J. Emerging therapeutic strategies for Parkinson’s disease and future prospects: a 2021 update. Biomedicines. 2022; 10(2): 371. DOI: 10.3390/biomedicines10020371
  4. Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease—repurposed drugs and new approaches. Nat Rev Neurol. 2019; 15: 204–223. DOI: 10.1038/s41582-019-0155-7
  5. Nakamori M, Junn E, Mochizuki H, Mouradian MM. Nucleic acid–based therapeutics for Parkinson’s disease. Neurotherapeutics. 2019; 16: 287–298. DOI: 10.1007/s13311-019-00722-3
  6. Wang R, Shih LC. Parkinson’s disease—current treatment. Curr Opin Neurol. 2023; 36(4): 302–308. DOI: 10.1097/WCO.0000000000001166
  7. Grétarsdóttir HM, Widman E, Johansson A, Nyholm D. Personalized medicine approach in treating Parkinson’s disease: benefits of six daily doses of levodopa. J Pers Med. 2021; 11(8): 720. DOI: 10.3390/jpm11080720
  8. Antonini A, Poewe W, Chaudhuri KR, et al. The long-term impact of levodopa/carbidopa intestinal gel on off-time in Parkinson’s disease. Adv Ther. 2021; 38(10): 5357–5374. DOI: 10.1007/s12325-021-01888-3
  9. Fox SH, Antonini A, Ferreira J. Tailoring motor fluctuation treatment: beyond levodopa dose adjustment. EMJ Neurol. 2022; 10(Suppl 1): 2–8. DOI: 10.33590/emj/10022165
  10. Johansson H, Folkerts AK, Hammarström I, Kalbe E, Leavy B. Effects of motor-cognitive training on dual-task performance in people with Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2023; 270(6): 2890–2907. DOI: 10.1007/s00415-023-11610-8
  11. Bucur M, Papagno C. Deep brain stimulation in Parkinson disease: a meta-analysis of the long-term neuropsychological outcomes. Neuropsychol Rev. 2023; 33(2): 307–346. DOI: 10.1007/s11065-022-09540-9
  12. Eldemir S, Eldemir K, Saygili F, et al. The effects of standard and modified LSVT BIG therapy protocols on balance and gait in Parkinson’s disease: a randomized controlled trial. Brain Behav. 2024; 14(3): e3458. DOI: 10.1002/brb3.3458